Merck to Acquire Immune Design
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
RBC Capital Downgrades Immune Design (IMDZ) to Sector Perform Following Takeover Deal
February 22, 2019 6:34 AM ESTRBC Capital analyst Brian Abrahams downgraded Immune Design (NASDAQ: IMDZ) from Outperform to Sector Perform with a price target of $6.00 (from $9.00).
The see the acquisition by MRK as highly likely to go through.
For an analyst ratings summary and ratings... More
Immune Design (IMDZ) to be Acquired by Merck for Massive Premium, Shares Surge
February 21, 2019 6:47 AM ESTImmune Design (NASDAQ: IMDZ) to be Acquired by Merck for Massive Premium, Shares Surge
... More